Navegando por Palavras-chave "Infliximabe"

Agora exibindo 1 - 2 de 2
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Ação modulatória da proteína Anexina A1 sobre os efeitos do tratamento com Anti-TNF-α em modelo murino de colite experimental
    (Universidade Federal de São Paulo (UNIFESP), 2016-07-26) Silva, Marina de Paula [UNIFESP]; Oliani, Sonia Maria [UNIFESP]; http://lattes.cnpq.br/5102737730539655; http://lattes.cnpq.br/6729268883239928; Universidade Federal de São Paulo (UNIFESP)
    The tumor necrosis factor-alpha (TNF-α) is a key cytokine in the triggering of the inflammatory bowel diseases (IBDs), constituting an interesting target to therapeutic strategies. However, anti-TNF-α drugs, such as the infliximab (IFX) can still promote side effects and non-responsiveness in some patients, bringing the need to investigate other mediators potentially related to the efficacy of this therapy. In the IBDs, the anti-inflammatory protein annexin A1 (AnxA1) has been associated to the protection of gastrointestinal mucosa. Here, we evaluated the role of the endogenous AnxA1 on the TNF-α blockage efficacy, in rodent model of colitis. To this end, we assessed the colitis induced by dextran sulphate sodium (DSS) in Balb/c mice. Mice deficient in AnxA1 (AnxA1-/-) were employed as an interesting tool to evaluate the relevance of this protein on the intestinal inflammatory condition, comparing with the wide type strain (WT). Mice were also treated with IFX after colitis induction. We consistently observed that the endogenous AnxA1 is related to the prevention of clinical and physiological manifestations on the experimental colitis treated with IFX, since no improvement was found in AnxA1-/- mice. On WT mice, the epithelial damages promoted by the DSS administration were prevented after treatment, which reduced the rectal bleeding and diarrhea, consequently. AnxA1 also preserves the colonic morphology after IFX by decreasing the histological score and protecting against collagen degradation. The interleukin-6 (IL-6) was increased during the colitis in WT and AnxA1-/- mice. The IFX treatment reduced this cytokine only in hte presence of AnxA1. The influx of neutrophils and TNF-? secretion were largely higher compared to WT. Phagocytes, which plays important pro-inflammatory roles, were more susceptible to apoptosis after IFX in the presence of AnxA1. The expression of endogenous AnxA1, was increased in the experimental colitis and decreased on treatment, showing that the inflammatory response is attenuated in this condition. We indicated, for the first time to our knowledge, that AnxA1 plays a critical role to the return of the intestinal homeostasis and constitute a potential biomarker of therapeutic efficacy.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Nível sérico de infliximabe no tratamento de crianças e adolescentes com doença de Crohn e colite ulcerativa
    (Universidade Federal de São Paulo (UNIFESP), 2019-04-01) Komati, Juliana Tiemi Saito [UNIFESP]; Sdepanian, Vera Lucia [UNIFESP]; http://lattes.cnpq.br/8273324982105660; http://lattes.cnpq.br/8273324982105660; http://lattes.cnpq.br/0846829387454978; http://lattes.cnpq.br/0846829387454978; Universidade Federal de São Paulo (UNIFESP)
    Objective: The objective of the study was to compare the Quantum Blue® Infliximab rapid test to ELISA RIDASCREEN® IFX Monitoring test in inflammatory bowel disease pediatric patients and the validation of Quantum Blue® Infliximab rapid test. Methods: The study was conducted at the Pediatric Gastroenterology Clinic of Federal University of São Paulo, in pediatric patients with Crohn's disease and ulcerative colitis who received infliximab maintenance treatment. Firstly, the samples were analyzed through Quantum Blue® Infliximab rapid test and then sent and analyzed by ELISA RIDASCREEN® IFX Monitoring assay and Quantum Blue® Infliximab, in Switzerland. Results: The mean age of patients was 13,7 ± 4,1 years; 51,7% masculine gender; 89,7% with Crohn´s disease and 10,3% with ulcerative colitis. Trough levels measured by Quantum Blue® Infliximab in Fleury and Switzerland had good reproducibility, with intraclass correlation coefficient = 0,81. There was a positive linear correlation (p < 0,001) between Quantum Blue® Infliximab Fleury and Switzerland and between ELISA RIDASCREEN® IFX Monitoring and both Quantum Blue® Infliximab, with Pearson’s correlation analysis. Conclusions: Quantum Blue® Infliximab test and ELISA RIDASCREEN® IFX Monitoring assay are comparable. The rapid test provides infliximab trough level in 15 minutes with accuracy, is user friendliness, and allows the dose adjustment in the next medication infusion.